Stevanato Group Achieves Record Revenue, Eyes Growth

Stevanato Group Spa ( (STVN) ) has released its Q4 earnings. Here is a breakdown of the information Stevanato Group Spa presented to its investors.

Stevanato Group S.p.A. is a global leader in providing drug containment, drug delivery, and diagnostic solutions primarily to the pharmaceutical, biotechnology, and life sciences industries. The company is renowned for its integrated, end-to-end portfolio of products and services that cater to the entire drug life cycle.

In its fiscal year 2024 earnings report, Stevanato Group announced a record revenue of €1,104 million, marking a 2% increase from the previous year. The company also introduced its 2025 guidance, projecting further revenue growth and improved earnings per share.

Key financial highlights for the fourth quarter of 2024 include a 3% increase in revenue to €330.6 million, driven by a 7% growth in the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions accounted for 40% of total revenue, reflecting strong demand for high-performance syringes. However, the Engineering Segment saw a decline, impacting the overall gross profit margin, which decreased to 29.7%.

For the full year, Stevanato Group’s adjusted EBITDA margin was 23.5%, with high-value solutions contributing significantly to the revenue mix. The company faced challenges such as vial destocking and inefficiencies from new manufacturing facilities but remains optimistic about its strategic investments and market positioning.

Looking ahead to 2025, Stevanato Group’s management remains focused on executing key priorities and achieving long-term objectives. The company expects to benefit from ongoing capacity expansions and aims to return to double-digit growth, expand margins, and enhance shareholder value.